Ganciclovir (Fresenius Kabi USA, LLC)
Welcome to the PulseAid listing for the Ganciclovir drug offered from Fresenius Kabi USA, LLC. This Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],DNA Polymerase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient],Nucleoside Analog Antiviral [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Fresenius Kabi USA, LLC |
| NON-PROPRIETARY NAME: | GANCICLOVIR SODIUM |
| SUBSTANCE NAME: | GANCICLOVIR SODIUM |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],DNA Polymerase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient],Nucleoside Analog Antiviral [EPC] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2010-06-28 |
| END MARKETING DATE: | 0000-00-00 |
Ganciclovir HUMAN PRESCRIPTION DRUG Details:
| Item Description | Ganciclovir from Fresenius Kabi USA, LLC |
| LABELER NAME: | Fresenius Kabi USA, LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 500(mg/10mL) |
| START MARKETING DATE: | 2010-06-28 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 63323-315_8d777a28-add1-412d-87c8-97f79c876f65 |
| PRODUCT NDC: | 63323-315 |
| APPLICATION NUMBER: | ANDA090658 |
Other GANCICLOVIR SODIUM Pharmaceutical Manufacturers / Labelers:
